Clinical Phenotypes and Dietary Management of Hepatic Glycogen Storage Disease Type 0

간 0형 당원축적병의 임상 표현형과 식사관리

  • Young-Lim Shin (Department of Pediatrics, Soonchunhyang University Bucheon Hospital, Soonchunhyang University College of Medicine)
  • 신영림 (순천향대학교 의과대학 소아청소년과학교실)
  • Published : 2023.12.31

Abstract

The hepatic glycogen storage disease type 0 (GSD type 0) is an autosomal recessive disorder caused by a deficiency of hepatic glycogen synthase encoded by the glycogen synthase 2 (GYS2) gene, leading to abnormal synthesis glycogen. The clinical findings of GSD type 0 are hyperketotic hypoglycemia at fasting state and accompanying postprandial hyperglycemia and hyperlactatemia. GSD type 0 has only been reported in a very small number so far, and the diagnosis is likely to be missed because symptoms are mild, severe hypoglycemia is rare or asymptomatic, or symptoms gradually disappear with age. Essential management strategies include feeding high-protein meals to stimulate gluconeogenesis, frequent meals to prevent hypoglycemia during the day and feeding complex carbohydrates such as uncooked cornstarch to slowly release glucose during nignt. GSD type 0 has a good prognosis, with appropriate treatment, normal growth can be achieved and no complications occur. Significant hypoglycemia occurs less common in adulthood, but ongoing dietary management may be necessary.

간 당원축적병 0형은 glycogen synthase 2 유전자에 부호화되어 있는 간 당원 합성효소의 결핍으로 비정상적으로 당원 생성이 되는 상염색체 열성 유전 질환이다. 당원축적병 0형의 임상 양상은 공복시에 고케톤혈증 저혈당증을 나타내고 식사후 고혈당과 고젖산혈증을 보인다. 당원축적병 0형은 현재까지 적은 수만 보고되었는데 증상이 경하거나 심한 저혈당이 드물고 또는 무증상이거나 나이가 듦에 따라 점차 증상이 사라지는 양상을 보이기 때문에 진단을 놓치는 경우가 있을 것으로 생각된다. 필수적 치료 전략은 포도당신생성을 자극하기 위해 고단백 식사, 낮동안 저혈당을 방지하기 위해서 잦은 식사 횟수, 밤 동안 천천히 포도당을 방출하기 위해 생옥수수전분가루 같은 복합 탄수화물을 먹는 것이다. 당원축적병 0형은 예후는 좋고 적절한 치료를 하면 정상적으로 성장하며 합병증도 발생하지 않는다. 성인이 될수록 심한 저혈당은 보이지 않게 되지만 지속적인 식사 관리는 필요하다.

Keywords

References

  1. Roach PJ, Depaoli-Roach AA, Hurley TD, Tagliabracci VS. Glycogen and its metabolism: some new developments and old themes. Biochem J 2012;441:763-87.  https://doi.org/10.1042/BJ20111416
  2. Gumus E, Ozen H. Glycogen storage diseases: An update. World J Gastroenterol 2023;29:3932-63.  https://doi.org/10.3748/wjg.v29.i25.3932
  3. McCorvie TJ, Loria PM, Tu M, Han S, Shrestha L, Froese DS, et al. Molecular basis for the regulation of human glycogen synthase by phosphorylation and glucose-6-phosphate. Nat Struct Mol Biol 2022;29:628-38.  https://doi.org/10.1038/s41594-022-00799-3
  4. Marr L, Biswas D, Daly LA, Browning C, Vial SCM, Maskell DP, et al. Mechanism of glycogen synthase inactivation and interaction with glycogenin. Nat Commun 2022;13:3372. 
  5. Ross KM, Ferrecchia IA, Dahlberg KR, Dambska M, Ryan PT, Weinstein DA. Dietary management of the glycogen storage diseases: evolution of treatment and ongoing controversies. Adv Nutr 2020;11:439-46.  https://doi.org/10.1093/advances/nmz092
  6. Beyzaei Z, Geramizadeh B, Karimzadeh S. Diagnosis of hepatic glycogen storage disease patients with overlapping clinical symptoms by massively parallel sequencing: a systematic review of literature. Orphanet J Rare Dis 2020;15:286. 
  7. Lewis GM, Spencer-Peet J and Stewart KM. Infantile hypoglycaemia due to inherited deficiency of glycogen synthetase in liver. Arch Dis Child 1963;38:40-8.  https://doi.org/10.1136/adc.38.197.40
  8. Arko JJ, Debeljak M, Tansek MZ, Battelino T, Groselj U. A patient with glycogen storage disease type 0 and a novel sequence variant in GYS2: a case report and literature review. J Int Med Res 2020;48:300060520936857. 
  9. Kasapkara CS, Aycan Z, Acoglu E, Senel S, Oguz MM, Ceylaner S. The variable clinical phenotype of three patients with hepatic glycogen synthase deficiency. J Pediatr Endocrinol Metab 2017;30:459-62.  https://doi.org/10.1515/jpem-2016-0317
  10. Kamenets EA, Gusarova EA, Milovanova NV, Itkis YS, Strokova TV, Melikyan MA, et al. Hepatic glycogen synthase (GYS2) deficiency: seven novel patients and seven novel variants. JIMD Rep 2020;53:39-44.  https://doi.org/10.1002/jmd2.12082
  11. Brown LM, Corrado MM, van der Ende RM, Derks TG, Chen MA, Siegel S, et al. Evaluation of glycogen storage disease as a cause of ketotic hypoglycemia in children. J Inherit Metab Dis 2015;38:489-93.  https://doi.org/10.1007/s10545-014-9744-1
  12. Weinstein DA, Correia CE, Saunders AC, Wolfsdorf JI. Hepatic glycogen synthase deficiency: an infrequently recognized cause of ketotic hypoglycemia. Mol Genet Metab 2006;87:284-8.  https://doi.org/10.1016/j.ymgme.2005.10.006
  13. Matei L, Teodorescu MI, Kozma A, Iordan Dumitru AD, Stoicescu SM, Carniciu S. Persistent asymptomatic severe hypoglycaemia due to type 0a Glycogenosis-general and oro-dental aspects. Acta Endocrinol (Buchar) 2019;15:526-30.  https://doi.org/10.4183/aeb.2019.526
  14. Spiegel R, Mahamid J, Orho-Melander M, Miron D, Horovitz Y. The variable clinical phenotype of liver glycogen synthase deficiency. J Pediatr Endocrinol Metab 2007;20:1339-42.  https://doi.org/10.1515/JPEM.2007.20.12.1339
  15. Soggia AP, Correa-Giannella ML, Fortes MA, Luna AM, Pereira MA. A novel mutation in the glycogen synthase 2 gene in a child with glycogen storage disease type 0. BMC Med Genet 2010;11:3. 
  16. Nessa A, Kumaran A, Kirk R, Dalton A, Ismail D, Hussain K. Mutation al analysis of the GYS2 gene in patients diagnosed with ketotic hypoglycaemia. J Pediatr Endocrinol Metab 2012;25:963-7.  https://doi.org/10.1515/jpem-2012-0165
  17. Hacihamdioglu B, Ozgurhan G, Caran B, Meydan-Aksanli E, Keskin E. Glycogen storage disease type 0 due to a novel frameshift mutation in glycogen synthase 2 (GYS2) gene in a child presenting with fasting hypoglycemia and postprandial hyperglycemia. Turk J Pediatr 2018;60:581-3.  https://doi.org/10.24953/turkjped.2018.05.018
  18. Chen MA, Weinstein DA. Glyogen storage diseases: diagnosis, treatment and outcome. Translat Sci Rare Dis 2016;1:45-72.  https://doi.org/10.3233/TRD-160006
  19. Heller S, Worona L, Consuelo A. Nutritional therapy for glycogen storage diseases. J Pediatr Gastroenterol Nutrition 2008;47:15-21.  https://doi.org/10.1097/MPG.0b013e3181818ea5
  20. Bachrach BE, Weinstein DA, Orho-Melander M, Burgess A, Wolfsdorf JI. Glycogen synthase deficiency (glycogen storage disease type 0) presenting with hyperglycemia and glucosuria: report of three new mutations. J Pediatr 2002;140:781-3.  https://doi.org/10.1067/mpd.2002.124317
  21. Ponzi E, Maiorana A, Lepri FR, Mucciolo M, Semeraro M, Taurisano R, et al. Persistent hypoglycemia in children: targeted gene panel improves the diagnosis of hypoglycemia due to inborn errors of metabolism. J Pediatr 2018;202:272-8.  https://doi.org/10.1016/j.jpeds.2018.06.050
  22. Massese M, Tagliaferri F, Dionisi-Vici C, Maiorana A. Glycogen storage diseases with liver involvement: a literature review of GSD type 0, IV, VI, IX and XI. Orphanet J Rare Dis 2022;17:241. 
  23. Nuttall FQ, Gannon MC, Kubic VL, Hoyt KJ. The human liver glycogen aynthase isozyme geneiIs located on the short arm of chromosome 12. Genomics 1994;19:404-5.  https://doi.org/10.1006/geno.1994.1086
  24. Aynsley-Green A, Williamson DH, Gitzelmann R. Hepatic glycogen synthetase deficiency. Definition of syndrome from metabolic and enzyme studies on a 9-year-old girl. Arch Dis Child 1977;52:573-9.  https://doi.org/10.1136/adc.52.7.573
  25. Chen YT, Cornblath M, Sidbury JB. Cornstarch therapy in type I glycogen storage disease. N Engl J Med 1984;310:171-5.  https://doi.org/10.1056/NEJM198401193100306
  26. Crigler JF, Folkman JI. Glycogen storage disease: new approaches to therapy. Ciba Found Symp 1978;55:331-51.  https://doi.org/10.1002/9780470720363.ch17
  27. Weinstein DA, Wolfsdorf JI. Effect of continuous glucose therapy with uncooked cornstarch on the long-term clinical course of type Ia glycogen storage disease. Eur J Pediatr 2002;161:35-9.  https://doi.org/10.1007/s00431-002-1000-2
  28. Kishnani PS, Goldstein J, Austin SL, Arn P, Bachrach B, Bali DS, et al. Diagnosis and management of glycogen storage diseases type VI and IX: a clinical practice resource of the American College of Medical Genetics and Genomics (ACMG). Genet Med 2019;21:772-89.  https://doi.org/10.1038/s41436-018-0364-2
  29. Wolfsdorf JI, Holm IA, Weinstein DA. Glycogen storage diseases: phenotypic, genetic, and biochemical characteristics and therapy. Endocrinol Metab Clin North Am 1999;28:801-23.  https://doi.org/10.1016/S0889-8529(05)70103-1
  30. Correia CE, Bhattacharya K, Lee PJ, Shuster JJ, Theriaque DW, Shankar MN, et al. Use of modified cornstarch therapy to extend fasting in glycogen storage disease types Ia and Ib. Am J Clin Nutr 2008;88:1272-6.  https://doi.org/10.3945/ajcn.2008.26352
  31. Ross KM, Brown LM, Corrado MM, Chengsupanimit T, Curry LM, Ferrecchia IA, et al. Safety and efficacy of long-term use of extended release cornstarch therapy for glycogen storage disease types 0, III, VI, and IX. J Nutri Thera 2015;4:137-42.  https://doi.org/10.6000/1929-5634.2015.04.04.5
  32. Ross KM, Brown LM, Corrado MM, Chengsupanimit T, Curry LM, Ferrecchia IA, et al. Safety and efficacy of chronic extended release cornstarch therapy for glycogen storage disease type I. JIMD Rep 2015;26:85-90.  https://doi.org/10.1007/8904_2015_488
  33. Bhattacharya K, Orton RC, Qi X, Mundy H, Morley DW, Champion MP, et al. A novel starch for the treatment of glycogen storage diseases. J Inherit Metab Dis 2007;30:350-7.  https://doi.org/10.1007/s10545-007-0479-0
  34. Tsilianidis LA, Fiske LM, Siegel S, Lumpkin C, Hoyt K, Wasserstein M, et al. Aggressive therapy improves cirrhosis in glycogen storage disease type IX. Mol Genet Metab 2013;109:179-82.  https://doi.org/10.1016/j.ymgme.2013.03.009
  35. Bhattacharya K. Investigation and management of the hepatic glycogen storage diseases. Transl Pediatr 2015;4:240-8. 
  36. Orho M, Bosshard NU, Buist NR, R Gitzelmann, A Aynsley-Green, P Blumel, et al. Mutations in the liver glycogen synthase gene in children with hypoglycemia due to glycogen storage disease type 0. J Clin Invest 1998;102:507-15. https://doi.org/10.1172/JCI2890